The Ovary Clock and the Five-Year Promise

"Too Good to Be True — Except We Know They're True"

On July 22, 2024, The Guardian ran a story with the headline that would define the next two years of women's longevity marketing: a drug could extend women's fertility by five years.¹ The reporting was sourced to interviews with two Columbia University researchers running a trial called VIBRANT. There was no paper. No preprint. No conference abstract. No press release, even. Two scientists talked to a journalist about early results, and a number entered the world.

The number was 20 percent — a claimed reduction in the rate of ovarian aging from low-dose rapamycin. One of the investigators, Dr. Yousin Suh, told the paper: "In a way, our results are too good to be true, except, because rapamycin is so well-studied, we know they are true."¹

Twenty-five months later, I went looking for the paper. There isn't one.

Not a publication in PubMed. Not a preprint on medRxiv. Not an indexed abstract from ASRM or ESHRE. Not results posted to ClinicalTrials.gov, where the trial's own registration lists an actual primary completion date of October 21, 2025 — ten months ago — and a hasResults flag of false.²

I want to be careful here, because this is not a story about bad scientists. The biology underneath this trial is legitimate and the trial itself is competently designed. It is registered, Phase 2, randomized, placebo-controlled, and triple-masked, at a serious academic center, run by an investigator with no financial stake in the answer. That is more rigor than most of what I review.

This is a story about what happened in the gap between a well-designed trial and a headline — and about who filled that gap with a monthly subscription.

Why the Ovary Became Longevity's Favorite Organ

Start with the part that is genuinely, unarguably true: the human ovary ages faster than almost anything else in the body, and it does so on a schedule set before birth.

The definitive quantification comes from Wallace and Kelsey, who built a model from eight histological studies covering 325 human ovaries, spanning seven weeks post-conception to age 51.³ Their finding is stark. By age 30, ninety-five percent of women retain only about 12 percent of their peak pre-birth follicle population. By 40, it is roughly 3 percent. Age alone explains 81 percent of the variance in how many follicles a woman has left.

That decline is not passive leakage. Primordial follicles sit dormant in the ovary, held asleep by active molecular suppression, and are recruited out of dormancy in a continuous trickle over four decades. Almost all of them die on the way. Roughly four hundred ever ovulate.

The brake on that dormancy is the PI3K–AKT–mTOR pathway. The cleanest proof came in 2008, when Reddy and colleagues deleted PTEN — the gene that restrains PI3K — specifically in mouse oocytes.⁴ Releasing the brake activated the entire primordial pool at once, and the mice burned through their reserve and hit premature ovarian failure. Published in Science. Replicated. Foundational.

So the logic writes itself: if lifting the brake burns the reserve, pressing the brake should conserve it. Rapamycin, an mTOR inhibitor, presses that brake.

And there is now good human tissue data pointing the same direction. Suh's own lab published a single-nucleus multi-omic atlas of young versus reproductively aged human ovaries in Nature Aging in 2025, finding more than three thousand genes changing with age in coordinated fashion — with mTOR signaling activated across multiple ovarian cell types.⁵ That is real, peer-reviewed, and good.

Fifty Women, Twelve Weeks, One Hormone

VIBRANT stands for Validating Benefits of Rapamycin for Reproductive Aging Treatment. That is a media name. The registered title on ClinicalTrials.gov is the considerably less cinematic "Effect of Rapamycin in Ovarian Aging," NCT05836025, sponsored solely by Columbia University, with Dr. Zev Williams as responsible party.²

Here is what the registry actually says, pulled fresh:

Read the primary endpoint again, because everything depends on it. Menopause timing was never measured. It was not a primary endpoint, not a secondary endpoint, and not mentioned in the registration. It could not have been. Menopause is diagnosed retrospectively, after twelve consecutive months without a period, at a median age around 51. These participants were 35 to 45 and took a pill for three months.

No study of this design can produce a number of years of menopause delay. The five years was an extrapolation from a biomarker slope, delivered verbally to a reporter.

There is also an arithmetic problem inside the original claim that nobody appears to have caught. The same Guardian paragraph that reports the 20 percent figure explains the mechanism this way: women lose about 50 eggs a month, and rapamycin slows that to 15 a month.¹ Fifty to fifteen is a 70 percent reduction. It is presented as 20 percent. Both numbers cannot describe the same effect, and no correction was ever published.

(I could not verify the "50 eggs a month" figure against any primary source, and it conflicts with the roughly one thousand non-growing follicles per month implied by Wallace and Kelsey's model.³ I am reporting it as an investigator's remark to a journalist, not as a fact from the literature.)

Here is the detail I find most telling. In July 2025, Suh presented this work to a scientific audience at the NIH's Wednesday Afternoon Lecture Series. The NIH's own write-up describes VIBRANT as "a proof-of-concept: it aimed to test the safety and feasibility of short-term rapamycin use and its potential effects on ovarian function."⁶

No 20 percent. No five years. Presented to peers, the claim reverted to what the trial was actually powered to show.

The Biomarker That Can't Do the Job

This is the deepest problem, and it is not a matter of opinion. It is extensively documented in the peer-reviewed literature that VIBRANT's primary endpoint cannot carry the claim being built on it.

Anti-Müllerian hormone, or AMH, is produced by small growing follicles and correlates with how many follicles a woman has left. It is a reasonable measure of ovarian reserve. It is a poor predictor of when any individual woman will reach menopause.

Sit with that. For a woman under 40, the uncertainty band on an AMH-based menopause prediction is somewhere between two and twelve years wide. The claimed benefit of rapamycin is five years. The measurement error swallows the effect whole.

There is no validated method for converting a 20 percent difference in AMH slope over twelve weeks into a number of years of menopause delay. Not a contested method. Not a controversial one. There is no method.

The field knows this. In a 2026 review in Fertility and Sterility, Eubanks and colleagues wrote the skeptical synthesis themselves.¹⁰ Speaking on the accompanying ASRM roundtable, the lead author put it plainly: AMH and antral follicle count "are surrogate markers of follicle activity. They're not direct markers of egg quality or reproductive competence." You can transiently move follicles that were already there, she noted, but "it doesn't necessarily mean that you've actually reversed the underlying biology of ovarian aging as it's sometimes being advertised as."

There is a second-order problem nobody has solved either. Suppose slowing recruitment works exactly as advertised, and the ovary empties later. Oocyte quality declines with chronological age independent of quantity; aneuploidy rates climb steeply through a woman's late thirties. Holding eggs dormant longer preserves the count while the eggs keep aging. The Guardian piece conceded this in its own text: whether the follicles will deteriorate over the extra time is "yet unknown."¹ A later-emptying ovary full of chromosomally abnormal eggs delays menopause without delivering the fertility benefit being sold.

What the Mice Said, and What PEARL Didn't Find

The animal data is real. It is also more ambivalent than the marketing suggests.

The foundational paper is Dou and colleagues in Aging Cell, 2017, showing that short-term rapamycin extended ovarian lifespan in young and middle-aged female mice.¹¹ The effect was most prominent in mice older than 12 months. That paper's own abstract contains the sentence the coverage dropped: application is limited "because of its detrimental effects on follicular development and ovulation during long-term treatment," with "disturbances in ovarian function during and shortly after treatment." Fertility returned to normal two months later.

A 2019 GeroScience study in 36 mice found rapamycin preserved primordial follicles at the expense of growing ones — and, in the same animals, induced insulin resistance.¹²

The translation gap is not small. Mice have three-week estrous cycles and do not undergo menopause. There is no mouse model of the thing being claimed.

Which brings us to PEARL, the trial that gets cited whenever someone wants human evidence that low-dose rapamycin does something good for women.

I want to be precise about what PEARL is and isn't. It is a real randomized placebo-controlled trial, which is more than most longevity compounds have. It also missed its primary endpoint, excluded dropouts from analysis, and generated its headline result from a subgroup of eight women, in a study authored entirely by people who profit from the drug.

As for human reproductive evidence: I searched ClinicalTrials.gov for every registered trial of sirolimus or rapamycin against ovarian aging, menopause, ovarian reserve, or infertility. NCT05836025 is the only one. Everything else that returns is oncology. There is no published randomized trial anywhere showing rapamycin delays human menopause. There is one unpublished trial of fifty women.

The nearest human reproductive RCT is a 2020 phase 2 study of sirolimus in recurrent implantation failure, which found meaningfully higher clinical pregnancy rates in women with elevated Th17/Treg ratios.¹³ That is a study about endometrial immune tolerance. It says nothing about ovaries.

The Contradiction Printed on the Box

Sirolimus is FDA-approved for exactly two things: prophylaxis of organ rejection in kidney transplant patients aged 13 and up, and treatment of lymphangioleiomyomatosis.¹⁴ That is the complete list. Every longevity use is off-label. There is no approved geroprotective indication for any drug.

The label carries a boxed warning for immunosuppression, increased infection susceptibility, and possible development of lymphoma and other malignancies. It states that only physicians experienced in immunosuppressive therapy should use it.

Now read the reproductive sections, keeping in mind that the target market is women who want to preserve fertility.

Set the pieces side by side. The FDA label says sirolimus shrinks ovaries and impairs fertility in rats, and causes ovarian cysts and amenorrhea in women. The foundational mouse paper says long-term treatment has detrimental effects on follicular development and ovulation.¹¹ And the Guardian article that launched the whole wave quotes the investigators conceding that too much rapamycin "could stop ovulation completely."¹

A drug being sold as fertility-extending is, at the wrong dose, fertility-suppressing. The entire proposition rests on a dose-response curve that has never been characterized in humans. That is not a footnote. That is the study that needs to exist.

What we actually know about low-dose safety in healthy adults comes largely from a survey of 333 off-label users — self-reported, unblinded, referral-biased, and framed by its own authors as preliminary.¹⁵ The better-controlled work uses rapalogs, not rapamycin, with immune endpoints, not ovarian ones. Mannick and colleagues showed in a 264-person phase 2a trial that low-dose mTOR inhibition improved immune function and reduced infections in older adults.¹⁶ Good science. Different drug, different organ, different question.

A Dosing Protocol From a Trial That Never Reported

Here is where I stop being charitable.

A telehealth longevity company publishes an article on rapamycin for women, dated May 2026, with a dosing table. One row reads: "Ovarian aging delay (under specialist oversight): 5 mg weekly (per VIBRANT protocol)." The same page states that in the VIBRANT pilot, the regimen "slowed ovarian follicle loss by approximately 20% and was well-tolerated." A purchase button sits on the same page.¹⁷

That is a commercial dosing protocol derived from a trial that has never reported a result. The 20 percent figure it cites traces back to a newspaper interview. The same article, further down, concedes that rapamycin for perimenopause "has not been directly studied in a randomized trial."

Compounded rapamycin runs about $64 to $65 a month at the major longevity telehealth companies, with "high absorption" formulations priced up to $121 and women's hormone memberships layered on top. One company markets that its users were "9 biological years younger on average in 1 year," with a footnote conceding the data was self-reported by 300 surveyed customers. Another claims an average 8-year biological age reduction, computed by a proprietary algorithm on paying customers with no control group.

To their credit, some players decline. Ro's own copy states: "We'll need more clinical trials in humans before rapamycin can be recommended for anti-aging." That is the correct position, and it is available to anyone who wants to take it.

On conflicts, I want to be fair and specific. Dr. Zev Williams, the trial's principal investigator, has no identifiable financial stake in the outcome. CMS Open Payments shows $72,687 in general payments from 2019 to 2025, roughly 92 percent of it speaker fees for an endometriosis drug in 2019 and 2020; his only entry in the last five years is a $47.41 meal. No rapamycin patent, no mTOR company. That is a clean record, and it matters.

Dr. Yousin Suh, the co-lead, discloses in one 2026 paper that she is "a scientific founder of Perpetual Biosciences." She is listed on the scientific advisory board of Elysium Health, a direct-to-consumer longevity supplement company, and as an advisor to LongeVC. None of these appear in the ClinicalTrials.gov registration or any public VIBRANT material, and the Perpetual disclosure is absent from two other papers she authored after taking those roles — including the Nature Aging ovarian paper, which states "the authors declare no competing interests."⁵

I am not alleging misconduct. Journals let authors judge relevance, and "no competing interests" is that judgment. The reportable fact is the pattern: the scientist whose verbal estimate became a five-year fertility claim has three commercial longevity affiliations that a reader of the trial registration would never see.

There is also a structural reason this went unchecked. Because there was never a paper, there was never an embargo. Because there was never an embargo, the Science Media Centre never ran an expert-reaction roundup, and the standard hype-check that fires on every major journal publication simply never fired. The claim entered public circulation through a door that has no gatekeeper.

And the trial that would settle this may never happen. Kara Goldman of Northwestern named the reason on the ASRM roundtable: rapamycin is off patent. "There are very few incentives for people to go do expensive trials." The definitive study is scientifically obvious, ethically necessary, and commercially unfinanceable.

Meanwhile the field around it is thinning. Oviva Therapeutics, working on recombinant AMH, was acquired by Granata Bio in April 2025 having never registered a clinical trial. Celmatix sold its portfolio to Gedeon Richter in March 2026, also with zero trial registrations. The one serious clinical program in reproductive longevity — Gameto's Fertilo, with a 500-patient Phase 3 now recruiting and a 2026 Cell Stem Cell paper behind it — is about maturing eggs for IVF, not delaying menopause.

A Real Target, an Empty Column